Research programme: antiinfective therapeutics - Maxwell Biosciences/United States Army Medical Research Institute of Infectious Diseases
Latest Information Update: 16 Jan 2024
At a glance
- Originator Maxwell Biosciences
- Developer Maxwell Biosciences; United States Army Medical Research Institute of Infectious Diseases
- Class
- Mechanism of Action Viral envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alphavirus infections; Bunyavirus infections; Orthopoxvirus infections; Paramyxoviridae infections; Viral haemorrhagic fevers
Most Recent Events
- 25 Oct 2023 Maxwell Biosciences and United States Army Medical Research Institute of Infectious Diseases entered a Cooperative Research and Development Agreement (CRADA) for antiinfective therapeutics
- 25 Oct 2023 Early research in Alphavirus Infections in USA (unspecified route)
- 25 Oct 2023 Early research in Bunyavirus infections in USA (unspecified route)